DVAX Share Price

Open 3.95 Change Price %
High 4.10 1 Day 0.10 2.53
Low 3.95 1 Week 0.05 1.25
Close 4.05 1 Month 0.10 2.53
Volume 567798 1 Year -13.68 -77.16
52 Week High 23.62
52 Week Low 3.20
DVAX Important Levels
Resistance 2 4.19
Resistance 1 4.13
Pivot 4.03
Support 1 3.97
Support 2 3.91
NASDAQ USA Most Active Stocks
DRYS 2.24 -4.68%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
MYRX 0.10 100.00%
LOCM 0.09 50.00%
CEMP 4.05 28.57%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
IPCI 2.55 18.60%
QKLS 0.15 15.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
GMETP 0.70 -59.54%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
EDMC 0.01 -50.00%
QTWW 0.08 -50.00%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Dynavax Technologies Corporation (NASDAQ: DVAX)

DVAX Technical Analysis 5
As on 24th Feb 2017 DVAX Share Price closed @ 4.05 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 11.68 & Strong Sell for SHORT-TERM with Stoploss of 4.17 we also expect STOCK to react on Following IMPORTANT LEVELS.
DVAX Target for February
1st Target up-side 4.51
2nd Target up-side 4.8
3rd Target up-side 5.08
1st Target down-side 3.69
2nd Target down-side 3.4
3rd Target down-side 3.12
DVAX Other Details
Segment EQ
Market Capital 770228480.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.dynavax.com
DVAX Address
DVAX
2929 Seventh Street
Suite 100
Berkeley, CA 94710
United States
Phone: 510-848-5100
DVAX Latest News
Dynavax Technologies Corporation (NASDAQ:DVAX) Quarterly EPS At $-0.86   Stock Observer   - 21st Feb 17
Dynavax In 2017: Hero Or Zero?   Seeking Alpha   - 19th Jan 17
Dynavax Technologies: Valuation Of The Immune-Oncology Pipeline   Seeking Alpha   - 18th Jan 17
Does Dynavax Need A Partner?   Seeking Alpha   - 01st Dec 16
SD-101: The Other Side Of Dynavax   Seeking Alpha   - 30th Nov 16
Dynavax CRL: The FDA Is Buying Time   Seeking Alpha   - 28th Nov 16
Dynavax Technologies: Lost Cause Or Time To Roll The Dice?   Seeking Alpha   - 16th Nov 16
Dynavax: What's Next For The Company?   Seeking Alpha   - 15th Nov 16
Will Dynavax' Hepsilav-B Ever Get Approved?   Seeking Alpha   - 14th Oct 16
Dynavax Technologies: An Updated View After FDA Decision   Seeking Alpha   - 08th May 16
Interactive Technical Analysis Chart Dynavax Technologies Corporation ( DVAX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Dynavax Technologies Corporation
DVAX Business Profile
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases. Its product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than licensed vaccines. The Company�s pipeline of product candidates includes HEPLISAV, its autoimmune program partnered with GlaxoSmithKline (GSK), its therapy for asthma partnered with AstraZeneca AB (AstraZeneca), and clinical-stage programs for its Universal Flu vaccine and hepatitis B therapy. As of December 31, 2011, its intellectual property portfolio included 18 issued United States patents, claiming compositions and formulations of immunostimulatory sequences (ISS) and Internal Revenue Service (IRS), their methods of use or processes for their manufacture.